Literature DB >> 3150849

Regulation of eicosanoid biosynthesis in vitro and in vivo by the marine natural product manoalide: a potent inactivator of venom phospholipases.

A M Mayer1, K B Glaser, R S Jacobs.   

Abstract

The marine natural produce manoalide has been reported to inactivate venom phospholipase A2 from several sources and phospholipase A2 from polymorphonuclear leukocytes. In this investigation, the regulation of eicosanoid production was studied both in an in vitro and in an in vivo model. The release of arachidonic acid and prostaglandin E2 was inhibited by manoalide when cultured mouse peritoneal macrophages were stimulated with phorbol myristate acetate (apparent IC50 = 0.23 microM), calcium ionophore A23187 (apparent IC50 = 0.23 microM) and zymosan (apparent IC50 = 0.18 microM). Leukotriene C4 production was inhibited by manoalide when macrophages were stimulated by A23187 (IC50 = 0.35 microM) but was enhanced when the cells were stimulated with zymosan. In an in vivo model, manoalide antagonized zymosan-induced peritoneal writhing in the mouse (ED50 = 0.71 mg/kg) and inhibited the i.p. release of 6-keto-prostaglandin F1 alpha (ED50 = 0.2 mg/kg) and leukotriene C4 (ED50 = 0.24 mg/kg). Our results suggest that: 1) manoalide modifies arachidonic acid release and metabolism to prostaglandins and leukotrienes in mouse cultured peritoneal macrophages stimulated by phorbol myristate acetate, calcium ionophore A23187 and zymosan and 2) the analgesic properties of manoalide seem to be partially correlated with reduced eicosanoid production in zymosan-stimulated mouse peritoneal exudates.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3150849

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Stimulated elastase release from human leukocytes: influence of anti-asthmatic, anti-inflammatory and calcium antagonist drugs in vitro.

Authors:  U Werner; O Seitz; I Szelenyi
Journal:  Agents Actions       Date:  1993

2.  Inhibition of phospholipase A2 activities and some inflammatory responses by the marine product ircinin.

Authors:  R Cholbi; M L Ferrándiz; M C Terencio; S De Rosa; M J Alcaraz; M Payá
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

3.  Pharmacological characterization of WAY-121,520: a potent anti-inflammatory indomethacin-based inhibitor of 5-lipoxygenase (5-LO)/phospholipase A2 (PLA2).

Authors:  K B Glaser; R P Carlson; A Sung; J Bauer; Y W Lock; D Holloway; R Sturm; D Hartman; T Walter; S Woeppel
Journal:  Agents Actions       Date:  1993

4.  Effect of a series of 1-alkyl ether lipids on inhibition of phospholipase A2 activity and PAF responses.

Authors:  C Kohler; M Carroll; E Tarrant; L Torley; A Wissner
Journal:  Inflammation       Date:  1993-06       Impact factor: 4.092

5.  The antiinflammatory activity of topically applied novel calcium-channel antagonists.

Authors:  G W De Vries; A McLaughlin; M B Wenzel; J Perez; D Harcourt; G Lee; M Garst; L A Wheeler
Journal:  Inflammation       Date:  1995-04       Impact factor: 4.092

6.  Effect of manoalide on human 5-lipoxygenase activity.

Authors:  F Cabré; A Carabaza; N Suesa; A M García; E Rotllan; M Gómez; D Tost; D Mauleón; G Carganico
Journal:  Inflamm Res       Date:  1996-05       Impact factor: 4.575

7.  Involvement of secretory phospholipase A2 activity in the zymosan rat air pouch model of inflammation.

Authors:  M Payá; M C Terencio; M L Ferrándiz; M J Alcaraz
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

8.  Differential modulation of microglia superoxide anion and thromboxane B2 generation by the marine manzamines.

Authors:  Alejandro M S Mayer; Mary L Hall; Sean M Lynch; Sarath P Gunasekera; Susan H Sennett; Shirley A Pomponi
Journal:  BMC Pharmacol       Date:  2005-03-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.